Vonoprazan-based triple therapy knocks out resistant H. pylori infection
        20 Nov 2020
    byJairia Dela Cruz 
        Vonoprazan-based triple therapy demonstrates potent activity and is well tolerated in the first-line treatment of patients with Helicobacter pylori, leading to high eradication of infection, including strains resistant to clarithromycin, as shown in a study from Japan.